114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肿瘤类器官的发展与应用：妇科癌症研究的新兴平台
Authors Hu Y, Chen W, Zhang X, Wu Y, Du F, Wang J, He M, Sun W
Received 12 September 2025
Accepted for publication 16 December 2025
Published 30 December 2025 Volume 2025:17 Pages 5761—5773
DOI https://doi.org/10.2147/IJWH.S567162
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Matteo Frigerio
Yu Hu,1,* Wei Chen,2,* Xiaojing Zhang,3,* Ying Wu,4 Furong Du,5 Jingrui Wang,5 Meijun He,4 Wei Sun6
1Laboratory Department, the People’s Hospital of Chuxiong Yi Autonomous Prefecture & the Fourth Affiliated Hospital of Dali University, Chuxiong, Yunnan, 675000, People’s Republic of China; 2Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China; 3Reproductive Health Research Institute, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 450000, People’s Republic of China; 4Department of Obstetrics and Gynecology, the 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, 650032, People’s Republic of China; 5Department of Medicine, Kingbio Medical Co., Ltd., Chongqing, 401123, People’s Republic of China; 6Department of General Internal Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Sun, Department of General Internal Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China, Email 13653402236@163.com Meijun He, Department of Obstetrics and Gynecology, the 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, 650032, People’s Republic of China, Email lovehmj-2008@163.com
Abstract: Gynecological cancers pose great health threats to women, in which ovarian cancer (OC), cervical cancer (CC) and endometrial cancer (EC) are most common. Conventional treatment modalities for gynecological cancers, such as surgery, chemotherapy and radiotherapy, are usually affected by multiple factors like drug resistance and recurrence. Organoids, a three-dimensional culture system derived from stem cells, have been demonstrated to recapitulate the biological structure and function of human organs and gradually used in the treatment of various cancer types, including gynecological cancers. The organoids established from gynecological cancers have patient tumor-dependent morphology and disease characteristics while retaining the tumor’s marker expression and genomic profiling, and present heterogeneous inter- and intra-patient drug responses, offering novel insights into drug response of the individual patients. This review provides an overview of recent advancements in the development and application of organoids from gynecological cancers, promoting the understanding of the mechanism underlying tumorigenesis, drug screening prediction and personalized treatment application in gynecological cancers.
Keywords: gynecological cancers, tumor organoids, drug screening, molecular mechanism, precision medicine
1Laboratory Department, the People’s Hospital of Chuxiong Yi Autonomous Prefecture & the Fourth Affiliated Hospital of Dali University, Chuxiong, Yunnan, 675000, People’s Republic of China; 2Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China; 3Reproductive Health Research Institute, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 450000, People’s Republic of China; 4Department of Obstetrics and Gynecology, the 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, 650032, People’s Republic of China; 5Department of Medicine, Kingbio Medical Co., Ltd., Chongqing, 401123, People’s Republic of China; 6Department of General Internal Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Sun, Department of General Internal Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China, Email 13653402236@163.com Meijun He, Department of Obstetrics and Gynecology, the 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, 650032, People’s Republic of China, Email lovehmj-2008@163.com
Abstract: Gynecological cancers pose great health threats to women, in which ovarian cancer (OC), cervical cancer (CC) and endometrial cancer (EC) are most common. Conventional treatment modalities for gynecological cancers, such as surgery, chemotherapy and radiotherapy, are usually affected by multiple factors like drug resistance and recurrence. Organoids, a three-dimensional culture system derived from stem cells, have been demonstrated to recapitulate the biological structure and function of human organs and gradually used in the treatment of various cancer types, including gynecological cancers. The organoids established from gynecological cancers have patient tumor-dependent morphology and disease characteristics while retaining the tumor’s marker expression and genomic profiling, and present heterogeneous inter- and intra-patient drug responses, offering novel insights into drug response of the individual patients. This review provides an overview of recent advancements in the development and application of organoids from gynecological cancers, promoting the understanding of the mechanism underlying tumorigenesis, drug screening prediction and personalized treatment application in gynecological cancers.
Keywords: gynecological cancers, tumor organoids, drug screening, molecular mechanism, precision medicine